Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $332.70M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.26M
Average 0.26M
VMD EBITDA Margin
EBITDA as a percentage of revenue.
Viemed Healthcare, Inc.NASDAQ: VMD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 15.8%
EBITDA Margin was 15.8% in Q1 FY2026, up 2.0 pp from a year earlier. On a trailing-twelve-month basis it was 18.5%, up 0.7 pp year over year. Over 3 fiscal years it widened by 1.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 17.8% for the fiscal year ending Dec 2026, down from 19.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 15.8%-5.1 pp QoQ
- Last fiscal yearDec 2025
- 19.1%+0.2 pp YoY
- LTMMar 2026
- 18.5%+0.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.0 pp | -0.0 pp | -2.0 pp |
| 1 year | +0.2 pp | -1.2 pp | -1.5 pp |
| 3 years | +1.2 pp | +1.3 pp | +0.1 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 19.1%
- Year-over-year change
- +0.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.1% | +0.2pp |
| FY2024 | 2024-12-31 | 18.9% | -1.2pp |
| FY2023 | 2023-12-31 | 20.0% | +2.2pp |
| FY2022 | 2022-12-31 | 17.9% | -2.7pp |
| FY2021 | 2021-12-31 | 20.6% | — |
EBITDA Margin vs competitors
How VMD compares with its peers on the latest reported figures
- VMD's LTM Mar 2026 EBITDA Margin of 18.5% is the 3rd highest of the 11 companies compared; the peer median is -49.5%.
- Its year-over-year change of +0.7 pp is the 9th highest of 11, against a peer median of +12.0 pp.
- Over three fiscal years its change of +1.2 pp compares with a peer median of +16.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 51.1% | +104.6 pp | +15.5 pp | |
| LTM Mar 2026 | 20.6% | +3.4 pp | +9.2 pp | |
| LTM Mar 2026 | 18.5% | +0.7 pp | +1.2 pp | |
| LTM Mar 2026 | -1.5% | +0.6 pp | +1.8 pp | |
| LTM Mar 2026 | -39.8% | +16.3 pp | +70.4 pp | |
| LTM Mar 2026 | -46.0% | +3.6 pp | +16.5 pp | |
| LTM Mar 2026 | -53.0% | +16.3 pp | +80.2 pp | |
| LTM Mar 2026 | -58.4% | -27.4 pp | -3.0 pp | |
| LTM Mar 2026 | -77.8% | +9.1 pp | +98.8 pp | |
| LTM Mar 2026 | -198.5% | +73.8 pp | -1165.0 pp | |
| LTM Dec 2025 | -376.3% | +15.0 pp | +506.1 pp | |
| Peer median (excluding VMD) | -49.5% | +12.0 pp | +16.0 pp | |
Competitors are the stored peer set for VMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 117.06M | 138.83M | 183.01M | 224.26M | 270.28M |
| Cost of Revenue | 43.65M | 54.15M | 70.23M | 91.05M | 114.82M |
| Gross Profit | 73.41M | 84.68M | 112.78M | 133.2M | 155.46M |
| Gross Margin | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% |
| Research & Development | 2.11M | 2.7M | 2.78M | 3.07M | 3.02M |
| Selling, General & Admin | 60.04M | 73.36M | 93.73M | 112.48M | 130.5M |
| Operating Expenses | 61.83M | 76.43M | 98.45M | 115.3M | 134.75M |
| Depreciation & Amortization | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M |
| EBITDA | 24.13M | 24.82M | 36.68M | 42.31M | 51.56M |
| EBITDA Margin | 20.6% | 17.9% | 20.0% | 18.9% | 19.1% |
| Operating Income | 11.58M | 8.25M | 14.33M | 17.9M | 20.71M |
| Operating Margin | 9.9% | 5.9% | 7.8% | 8.0% | 7.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 318K | 197K | 424K | 776K | 1.18M |
| Other Income / Expenses | 923K | 738K | 61K | (1.73M) | 1.06M |
| Income Before Tax | 12.5M | 8.99M | 14.39M | 16.17M | 21.77M |
| Pre-Tax Margin | 10.7% | 6.5% | 7.9% | 7.2% | 8.1% |
| Income Tax Expense | 3.38M | 2.77M | 4.15M | 4.76M | 6.39M |
| Net Income | 9.13M | 6.22M | 10.24M | 11.27M | 14.93M |
| Net Margin | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| EPS (Basic) | 0.23 | 0.15 | 0.27 | 0.29 | 0.38 |
| EPS (Diluted) | 0.22 | 0.15 | 0.25 | 0.28 | 0.37 |
| Weighted Avg Shares | 39.49M | 38.66M | 38.35M | 38.76M | 38.9M |
| Weighted Avg Shares (Diluted) | 40.68M | 39.81M | 40.38M | 40.81M | 40.82M |
Viemed Healthcare, Inc.
NASDAQ:VMD
Intrinsic Alpha fair value
Locked
Current Price
$8.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.